Q-omics provides the consensus-scored TMEM105 profile across patient tissues and cancer cell-line models. TMEM105 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TMEM105 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, TMEM105 RNA expression shows 14,105 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, COAD, and TGCT as cancer lineages where TMEM105 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM105 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM105 survival associations across molecular data types. TMEM105 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM105 RNA expression–survival associations across cancer types. High TMEM105 expression shows unfavorable associations in KIRP, ACC, BRCA and HNSC, but favorable associations in SCLC and DLBC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TMEM105 RNA expression.
This table summarizes TMEM105 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM105. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM105 shows lower tumor expression in KIRC and KICH and higher tumor expression in COAD, THCA, HNSC and LUAD. The COAD box plot shows higher TMEM105 RNA expression in tumor versus normal tissue (log2 FC = +1.365, t-test p < 0.001).
This table shows molecular features associated with TMEM105 in patient tissues and cancer cell lines. In patient samples, TMEM105 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM105 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD.
